Clinical Trial Update: A Study of Viral Response to Triple Therapy in Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy (MK-3034-113) [Phase 4]

View source ↗

Summary

Phase 4 trial MK-3034-113 investigating triple therapy for Hepatitis C in insulin-resistant patients who failed dual therapy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• MK-3034

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C | Phase 4 | Status: WITHDRAWN